IONS today
$27.31-$1.02 (-3.60%)close Nov 12, 2026Trend
DailyUptrend (starting)
4 hourStrong Bearish
1 hourSymmetric Triangle
15 minBullish
5 minExpanding
Daily trend turns down below $42.08
Key levels
Resistance$31.66
Resistance$28.79
Support$23.95
Support$20.49
Latest news & SEC filings
ProductIonis Pharmaceuticals reports extended DAWNZERA findings at ACAAI 2026
AnalystBarclays trims Ionis Pharmaceuticals target to $70, maintains Overweight rating
AnalystGoldman Sachs keeps Neutral rating on Ionis Pharmaceuticals, cuts price target to $41
AnalystMorgan Stanley keeps Overweight on Ionis Pharmaceuticals, cuts target to $75
All IONS news →About Ionis Pharmaceuticals
Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines for serious diseases. Its marketed products include treatments for familial chylomicronemia syndrome, hereditary angioedema, hereditary transthyretin-mediated amyloidosis, spinal muscular atrophy, SOD1-ALS, and related conditions. The company sells some medicines independently in the United States and works with partners such as Biogen, AstraZeneca, Otsuka, and Sobi to commercialize products in Europe, Asia, Latin America, and other regions. Its pipeline focuses on neurology, cardiometabolic disease, and other areas of high unmet need.
Based on the company's 10-K filed Feb 26, 2026.
Nasdaq · Healthcare
IONIS PHARMACEUTICALS INC (IONS)
What Is the Price Target for IONS?
SEPT Low Target
$41.00
SEPT Mid Target
$70.00
SEPT High Target
$100.00
Analyst Consensus
$70.00
Is IONS a Buy or Sell Right Now?
Thesis
- •Revenue growing 33.8% YoY with STRONG trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for IONS.
Start Free Trial →Is IONS Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$54.20
13
Moat Score
NONE
3/9
Piotroski Score
0.6
Altman Z-Score
What Is Smart Money Doing with IONS?
Insider Signal
SELLING
0 buys / 6 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| BENNETT C FRANK | officer | Buy | 110 | $6K | Aug 31, 2026 |
| O'NEIL PATRICK R. | officer | Buy | 63 | $3K | Aug 31, 2026 |
| Monia Brett P | director officer | Buy | 98 | $5K | Aug 31, 2026 |
| Birchler Brian | officer | Buy | 58 | $3K | Aug 31, 2026 |
| HERMAN JOAN E | director | Buy | 5,220 | - | Jul 15, 2026 |
| BERTHELSEN SPENCER R | director | Buy | 5,220 | - | Jul 15, 2026 |
| Baroldi Joseph | officer | Buy | 3,866 | $220K | Jun 26, 2026 |
| Baroldi Joseph | officer | Buy | 1,769 | $58K | Jun 26, 2026 |
| Baroldi Joseph | officer | Sale | 5,635 | $452K | Jun 26, 2026 |
| O'NEIL PATRICK R. | officer | Sale | 3,069 | $246K | Jun 26, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →IONS Growth Story
Revenue YoY
33.8%
3yr Revenue CAGR
17.1%
EPS Growth YoY
21.71%
FCF Growth YoY
N/A%
Revenue Trend
STRONG
Dark Pool Trades for IONS
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for IONS, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:08 | $27.31 | 1,104 | $$30K | SELL |
| 21:00:08 | $27.31 | 21,488 | $$587K | SELL |
| 21:00:08 | $27.31 | 3,171 | $$87K | SELL |
| 21:00:08 | $27.31 | 2,865 | $$78K | SELL |
| 21:00:08 | $27.31 | 1,223 | $$33K | SELL |
5 dark pool trades shown · $$815K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for IONS
PREVIEWSEPT Investing provides real-time options flow tracking for IONS, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $32.5 | Nov 20 | 8 | $$10 | 1 | SWEEP |
| PUT | $50 | Apr 16 | 155 | $$2206 | 1 | SWEEP |
| PUT | $45 | Dec 17 | 400 | $$1837 | 1 | SWEEP |
| CALL | $22.5 | Jan 15 | 64 | $$180.0K | 300 | BLOCK |
| PUT | $17.5 | Apr 16 | 155 | $$69.9K | 999 | BLOCK |
5 options trades shown · 40% calls
Unusual activity, GEX levels, max pain, and dealer positioning
What Traders Are Saying About IONS
1 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for IONS. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
SEPT Brain on $IONS -- Neutral IONS $74.09 (down 1.7% from yesterday, eod session). BIG PICTURE: FOR upside: Daily uptrend. Timeframes mostly bullish (daily up, 1hour up, 15min range). Support at $7...
Join 3,500+ traders discussing IONS in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for IONIS PHARMACEUTICALS INC (IONS) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (9 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →IONS — frequently asked questions
What is IONS stock price today?
IONIS PHARMACEUTICALS INC (IONS) is at $27.31, down 3.60% (-$1.02) at the Nov 12, 2026 close.
Why is IONS stock moving today?
Latest IONS news — Nov 12, 2026: Ionis Pharmaceuticals reports extended DAWNZERA findings at ACAAI 2026 · Nov 11, 2026: Barclays trims Ionis Pharmaceuticals target to $70, maintains Overweight rating
Why did IONS stock move on Nov 9, 2026?
Ionis Pharmaceuticals reported third-quarter adjusted loss per share of $0.40, narrower than the $(1.21) estimate, while revenue of $243.000M topped the $182.117M forecast. However, the company reaffirmed full-year 2026 sales guidance of $875M-$900M, below the $916.396M analyst estimate, and a law office opened a probe after the company trimmed its sales forecast.
What is the IONS price target?
The average analyst price target for IONS is $70.00, ranging from $41 to $100, based on 13 analysts. Latest: HC Wainwright & Co. maintains on Nov 10, 2026.
What do analysts rate IONS?
Analyst ratings for IONS: 1 Buy, 45 Hold, 1 Sell — consensus Hold.
Did IONS beat earnings?
IONS last reported on Nov 9, 2026: EPS -$0.40 vs -$1.21 expected — a beat of 66.9%.
Does IONS pay a dividend?
IONS does not currently pay a dividend.
What are IONS support and resistance levels?
Support: $23.95, $20.49. Resistance: $28.79, $31.66, $34.77.
What are insiders doing with IONS?
Insider activity: SELLING, 0 buys and 6 sells in the last 90 days.
What is the latest news on IONS?
Nov 12, 2026: Ionis Pharmaceuticals reports extended DAWNZERA findings at ACAAI 2026 · Nov 11, 2026: Barclays trims Ionis Pharmaceuticals target to $70, maintains Overweight rating · Nov 10, 2026: Goldman Sachs keeps Neutral rating on Ionis Pharmaceuticals, cuts price target to $41